| name | es-hcm-ugps7-oncology-consult |
| description | This skill recommends obtaining an oncology consultation to direct treatment of the underlying malignancy causing hypercalcemia of malignancy. It is triggered when a clinician diagnoses HCM and seeks guidance on coordinating cancer‑directed therapy. |
Obtain clinical oncology consultation for underlying malignancy treatment
STEP 1 — Gather Information
Confirm hypercalcemia of malignancy (serum calcium >12 mg/dL with malignancy history), assess symptoms (fatigue, polyuria, confusion), identify cancer type (e.g., lung, breast, myeloma), and review prior antiresorptive therapy.
STEP 2 — Rule In / Rule Out
Is HCM confirmed and malignancy‑related? If yes, proceed to step 3; if no, consider alternative causes (e.g., hyperparathyroidism, vitamin D excess) and manage accordingly.
STEP 3 — Classify or Stratify
Stratify HCM severity: mild (Ca<12 mg/dL), moderate (12‑14 mg/dL), severe (>14 mg/dL). For severe HCM, prioritize urgent oncology input; for mild/moderate, schedule timely consultation.
STEP 4 — Decide
Obtain clinical oncology consultation to direct cancer‑directed treatment (chemotherapy, targeted therapy, radiation) aimed at controlling the underlying malignancy and preventing HCM recurrence.
Clinical Guardrails / Mimics / Pitfalls
Do not delay oncology consult while awaiting antiresorptive effect; do not assume HCM will resolve with bisphosphonates/denosumab alone; avoid overlooking histologic confirmation of malignancy; do not ignore renal dysfunction when planning oncology‑directed regimens.
Concrete Clinical Example
A 62‑year‑old with known non‑small cell lung cancer presents with nausea and lethargy; serum calcium is 15.2 mg/dL, confirming severe HCM. Oncology is consulted urgently to initiate pembrolizumab and radiation, leading to calcium normalization within 48 hours.
Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621
